The Walden Group is pleased to provide access to its 2023 Year-end Strategic Healthcare M&A Report …

The Walden Group releases its 2024 Medical Device Outsourcing Developments report.

The Walden Group is pleased to provide access to its Q3 2023 Strategic Healthcare M&A Report, which includes:        Q3 2023 Market Overview      Noteworthy M&A Deals By Sector      Top Deals > $100m in Transaction Value Announced or Closed in Q3 2023      Performance of Leading Healthcare Companies      Analysis of More Than 45 Q3 M&A …

The Walden Group is pleased to provide access to its Q2 2023 Strategic Healthcare M&A Report, which includes:        Q2 2023 Market Overview      Noteworthy M&A Deals By Sector      Top Deals > $100m in Transaction Value Announced or Closed in Q2 2023      Performance of Leading Healthcare Companies      Analysis of More Than 45 Q2 M&A …

The Walden Group is pleased to provide access to its Q1 2023 Strategic Healthcare M&A Report, which includes:        Q1 2023 Market Overview      Noteworthy M&A Deals By Sector      Top Deals > $100m in Transaction Value Announced or Closed in Q1 2023      Performance of Leading Healthcare Companies      Analysis of More Than 45 Q1 M&A …

Spain-based manufacturer and distributor of diagnostic instruments Werfen has acquired Immucor, a manufacturer of transfusion and transplant diagnostic devices.  The acquisition adds platelet detection, diagnostic analyzers, blood monitoring and molecular testing products that help match patients and donors.  Deal terms — $2b. Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Medical Devices; Diagnostics

The Walden Group is pleased to provide access to its Q4 2022 Strategic Healthcare M&A Report, which includes:       Recent Divestitures and Spin-Offs     Diagnostic and Medical Device Deals with Valuations over $100m     Noteworthy M&A Deals By Sector     Top Deals > $100m in Transaction Value Announced or Closed in 2022     Performance of …

Shockwave Medical, a $237m developer of technologies treating calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve disease, is acquiring Neovasc, a $2.5m Canada-based developer of transcatheter devices treating refractory angina and mitral valve disease.  Deal terms – $100m upfront plus $47m in milestones on sales of $2.5m (40x).     Keywords: Healthcare Investment Banking, Healthcare M&A, …

Zimmer Biomet Holdings, Inc., a $8.0b maker of orthopedic reconstructive products is acquiring Embody, Inc., a developer of collagen implants for repairing tendons, ligaments and torn rotator cuffs.  The acquisition builds Zimmer Biomet’s sports medicine offerings after it spun-off its dental and spine operations into Zimvie, a separate, publicly-traded company in March 2022.  Deal value – $155m plus $120m in …

The Walden Group is pleased to announce that it represented Total Titanium, Inc. (TTI) in its sale to a subsidiary of Bausch + Lomb Corporation (NYSE/TSX:BLCO) (“Bausch + Lomb”). TTI was one of the last remaining independently-owned manufacturers of precision ophthalmic instruments based in the United States. Bausch + Lomb is a leading global eye health company dedicated to helping people …